Vendor Intelligence Report: LSPL
Published 12 Nov 2026. 38-page investigative report on who is behind LSPL: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.
Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.
Executive summary
Across 57 Finnrick lab tests, LSPL shows 40 pass / 17 fail for a 70% overall pass rate. The average hides a product-specific split: GHK-Cu is the comparatively stronger tested choice, Tirzepatide is mixed and needs current batch verification, and Retatrutide is the clear weak point among the well-tested products. The full report also shows ratings tightening under stricter grading.
The identity file is thinner than the lab file. LSPL’s public contact surface is a gated Facebook profile, with no standalone LSPL storefront or public LSPL corporate registration located. The strongest accountability trail runs through a forum-reported ZZQ affiliation, a published xtxinyao.cn email domain, and a Chinese IT/email-services registrant; it helps authenticate channels but does not resolve owner, manufacturer, QA lead, or batch-release authority.
The storefront map is crowded. ZZQ, Quenna, MingYu, and Yanmi share combinations of addresses, phones, mail domains, sales personas, template text, and hosting, while older clone domains have expired, parked, or gone dark. A separate SEO hijack network uses LSPL and ZZQ search terms to redirect buyers into WhatsApp groups; the evidence supports brand-jacking, not proven LSPL control.
The non-lab record reinforces the need for batch-level caution: forum records include a moderator ban for incentivized positive reviews, cloudy-reconstitution and underfill complaints, refund-stalling allegations, wrong-shipment reports, and disputed COA handling. None of that replaces lab data, but it matters where public terms, staff, and batch-release controls are not auditable.
Inside the full report:
- Appendix A with per-product pass/fail rates and methodology-divergence charts for all 5 tested products
- ZZQ, xtxinyao.cn, and Haigui domain/registrant chain with source captures
- Storefront-network analysis for Quenna, MingYu, Yanmi, Sunnysky, LiYu, and collapsed clone domains
- Forum incident chronology covering the GLP-1 Forum ban, COA allegations, refunds, and fulfillment complaints
- SEO-hijack redirect-chain analysis from institutional doorway pages to third-party WhatsApp groups
Risk assessment
- Retatrutide quality risk — high: LSPL Retatrutide is 64.5% on 24 tests, 14 pass / 10 fail, making it the weak point among the well-tested products.
- Tirzepatide quality risk — medium: LSPL Tirzepatide is 77.26% on 21 tests, 16 pass / 5 fail; mixed rather than failing, but requires current batch-specific verification.
- COA integrity risk — high: LSPL/ZZQ have no public verifiable batch-COA system; forum users allege cross-posted and outdated tests, and Quenna’s COA claims are unsupported by visible certificates.
- Undisclosed incentivized-review risk — high: A GLP-1 Forum moderator banned Ava Smith/Peilun/LSPL on 2025-03-20 for incentivizing positive reviews and said LSPL praise could not be authenticated.
- Vendor transparency and manufacturing-accountability risk — high: No LSPL legal entity, standalone site, named QA staff, GMP record, facility proof, or batch-release authority was found; ZZQ’s email domain is registered to an IT/email services provider.
- Brand-confusion and channel-authentication risk — high: LSPL has a gated Facebook-only contact surface, overlapping ZZQ/Quenna/MingYu/Yanmi identifiers, a false Lifestyle Peptides directory conflation, and active third-party SEO hijacks to WhatsApp groups.
- Dispute-resolution and customer-data risk — high: Forum reports include refund stalling, blocking, wrong shipments, payment-tracking failures, and alleged sharing of customer transaction screenshots; the private-chat model leaves little recourse.
- Affiliated-storefront product-scope risk — medium: ZZQ’s catalog includes testosterone enanthate, Superdrol, HGH, and NAD+ alongside peptides; the LSPL-to-ZZQ link is medium-confidence, but buyers routed through ZZQ face added legal and safety exposure.